Jiuhong (Jonathan) Z.

1. Constructed robust quantitative valuation models for late-stage (pivotal) clinical assets, synthesizing data across commercial, clinical, and market access teams to evaluate commercial viability and drive executive Go/No-Go decisions. 2. Spearheaded comprehensive scientific evaluations of pre-clinical and post-PoC oncology pipelines (GI cancer), translating complex multidimensional data into actionable reports for strategic portfolio prioritization and capital allocation. 3. Landscape mapping & Competitive Intelligence: Monitored the evolving gastrointestinal cancer therapeutic landscape by regularly reviewing competitive intelligence, attending key scientific and industry conferences, and disseminating strategic insights to inform pipeline strategy and positioning. 4. Value Creation & Lifecycle Management: Directed the end-to-end progression of flagship assets via Global Product Teams (GPT), aligning cross-functional global strategies to accelerate development and achieve critical value inflection points. 5. Evaluated external ophthalmology pipeline assets for in-licensing potential, preparing comprehensive scientific, clinical, and commercial assessment reports to support senior management investment decisions.

1. Deal Evaluation & Valuation: Spearheaded buy-side evaluation for potential in-licensing opportunities, conducting rigorous cross-functional due diligence and constructing financial models (e.g., rNPV) to drive strategic investment decisions. 2. Post-Deal Governance (Alliance Management): Directed post-transaction alliance management for a high-value cardiovascular asset, steering corporate governance via Joint Development and Commercialization Committees (JDC/JCC) to align strategic objectives with external partners. 3. Cross-Functional Execution & Value Realization: Orchestrated matrix teams spanning Clinical, CMC, Medical Affairs, and Commercial to ensure strict adherence to contractual terms and the timely realization of partnership milestones.

1.  Asset Lifecycle Management: Managed a portfolio of complex CMC programs for international clients, advancing projects from early development (DRF/GLP) through Phase I/II/III and commercial (PPQ campaigns), ensuring seamless progression across the full drug development lifecycle. 2. Risk Mitigation & Milestone Delivery: Proactively identified technical and operational vulnerabilities within complex cross-functional pipelines, executing robust mitigation strategies to safeguard critical timelines and quality standards. 3. Commercial & Financial Oversight: Structured and negotiated technical contracts while rigorously managing project scope and change orders, optimizing capital deployment and preventing R&D budget overruns for international sponsor

1. API & Intermediate Process Development: Designed, executed, and optimized synthetic routes and scale-up strategies for Active Pharmaceutical Ingredients (APIs) and key intermediates, driving improvements in yield, cost efficiency, and manufacturing robustness. 2.   End-to-End Process Scale-Up: Championed process research and development across the full development continuum — from laboratory discovery through kilo-lab validation to pilot plant manufacturing — ensuring seamless technology transfer and production readiness at each stage.

• Give pre-lab lectures on related chemistry and safety precautions • Instruct the students how to perform the commonly used lab techniques • Guide the students through trouble-shooting